$50 Million

Editas Medicine

At-the-market Offering

Editas Medicine
Editas is a genome editing company focused on developing treatments for patients with genetically defined diseases by correcting their disease-causing genes. The Company has developed a proprietary genome editing platform based on CRISPR/Cas9 technology. This platform consists of medicines that specifically address a wide variety of genetic targets, that reach the site of disease safely and effectively, that tightly and specifically control the editing process, and that drive the right kind of genetic repair. The Company’s platform uses the flexibility of CRISPR/Cas9 technology to enable rapid reprogramming of the technology to direct it to almost any site in the human genome, enabling the efficient development of potential therapies for a broad range of genetically defined diseases.